Please login to the form below

Not currently logged in
Email:
Password:

Dapagliflozin meets goals of late-stage study

Bristol-Myers Squibb and AstraZeneca's diabetes drug dapagliflozin has met the main goals of a phase III trial

BMS and AZ's diabetes drug dapagliflozin met the main goals of a phase III trial. It was proven that the drug was more effective than an older treatment at reducing blood sugar levels.

Dapagliflozin is a first-in-class sodium-glucose cotransporter-2 (SGLT2) inhibitor being developed as a once-daily oral therapy for the treatment of adult patients with type 2 diabetes.

The trial enrolled 597 patients with type 2 diabetes that was inadequately controlled with at least half the recommended dose of glimepiride. The companies said a combination of dapagliflozin and glimepiride was better at reducing blood sugar levels than glimepiride and a placebo.

Patients on dapagliflozin also lost more weight, had greater oral glucose tolerance and lower blood sugar levels between meals after the 24-week late stage clinical trial.

Side-effects were similar for dapagliflozin and glimepiride, but patients on dapagliflozin were more likely to have genital tract infections.

Results from the trial were presented at a meeting of the European Association for the Study of Diabetes in Stockholm.

21st September 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OPEN Access Consulting

OPEN Access Consulting is a specialist market access agency within the OPEN Health Group. As value communications experts we specialise...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics